Company Filing History:
Years Active: 2020-2022
Title: Ken Uchibori: Innovator in Lung Cancer Therapeutics
Introduction
Ken Uchibori is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of cancer research, particularly in developing therapeutic agents for lung cancer. With a total of 2 patents, Uchibori's work focuses on overcoming challenges associated with chemotherapy resistance in non-small cell lung cancer.
Latest Patents
Uchibori's latest patents include a groundbreaking therapeutic agent for lung cancer that has acquired EGFR-TKI resistance. This innovative drug contains active ingredients represented by ALK inhibitors such as brigatinib, AP26113-analog, and AZD3463. It has been found effective against non-small cell lung cancer with a point mutation at C797S in EGFR, which has developed resistance to traditional chemotherapy agents. Furthermore, when used in combination with an anti-EGFR antibody, this drug demonstrates a notable suppression effect on tumor growth. It holds the potential to serve as an effective therapeutic agent against non-small cell lung cancer resistant to gefitinib, a first-generation therapeutic agent, and osimertinib, a third-generation therapeutic agent.
Career Highlights
Ken Uchibori is affiliated with the Japanese Foundation for Cancer Research, where he continues to advance his research and innovations in cancer therapeutics. His work is pivotal in addressing the pressing need for effective treatments for patients facing chemotherapy resistance.
Collaborations
Uchibori collaborates with esteemed colleagues, including Ryohei Katayama and Naoya Fujita, to further enhance the impact of his research in the field of oncology.
Conclusion
Ken Uchibori's contributions to lung cancer therapeutics exemplify the critical role of innovation in medicine. His work not only addresses significant challenges in cancer treatment but also offers hope for patients battling resistant forms of the disease.